SCHEMBL18280899

SCHEMBL18280899

CC1CC2=CCCCCCCCCCC2C1

nearest known ligand 0.33

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18280898 1.00 KDM1A (0.33) KDM1A
SCHEMBL2264806 0.79
SCHEMBL2264803 0.79
SCHEMBL11071002 0.79 KDM1A (0.35) KDM1A
SCHEMBL31290727 0.79
SCHEMBL11071014 0.79 KDM1A (0.35) KDM1A
SCHEMBL28100320 0.78 TLR4 (0.34)
SCHEMBL28100321 0.78 TLR4 (0.34)
SCHEMBL15775089 0.77
SCHEMBL235344 0.73 KDM1A (0.48) KDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250214920-A1 METHOD FOR PRODUCING CYCLIC DIKETONE COMPOUND KAO CORPORATION (JP) 2025-07-03 US claimed
US-20250214921-A1 METHOD FOR PRODUCING CYCLIC DIKETONE COMPOUND KAO CORPORATION (JP) 2025-07-03 US claimed
EP-4501896-A1 METHOD FOR PRODUCING CYCLIC DIKETONE COMPOUND Kao Corporation (JP) 2025-02-05 EP claimed
EP-4501897-A1 METHOD FOR PRODUCING CYCLIC DIKETONE COMPOUND Kao Corporation (JP) 2025-02-05 EP claimed
CN-118973991-A Process for producing cyclic diketone compound 花王株式会社 2024-11-15 CN claimed
CN-118973990-A Process for producing cyclic diketone compound 花王株式会社 2024-11-15 CN claimed
WO-2023189722-A1 METHOD FOR PRODUCING CYCLIC DIKETONE COMPOUND 花王株式会社 2023-10-05 WO claimed
WO-2023189723-A1 METHOD FOR PRODUCING CYCLIC DIKETONE COMPOUND 花王株式会社 2023-10-05 WO claimed
CN-107709283-B Process for preparing 3-methylcyclopentadecane-1, 5-dione 巴斯夫欧洲公司 2021-02-02 CN claimed
US-20250214920-A1 METHOD FOR PRODUCING CYCLIC DIKETONE COMPOUND KAO CORPORATION (JP) 2025-07-03 US disclosed
US-20250214921-A1 METHOD FOR PRODUCING CYCLIC DIKETONE COMPOUND KAO CORPORATION (JP) 2025-07-03 US disclosed
EP-4501896-A1 METHOD FOR PRODUCING CYCLIC DIKETONE COMPOUND Kao Corporation (JP) 2025-02-05 EP disclosed
EP-4501897-A1 METHOD FOR PRODUCING CYCLIC DIKETONE COMPOUND Kao Corporation (JP) 2025-02-05 EP disclosed
CN-118973991-A Process for producing cyclic diketone compound 花王株式会社 2024-11-15 CN disclosed
WO-2023189722-A1 METHOD FOR PRODUCING CYCLIC DIKETONE COMPOUND 花王株式会社 2023-10-05 WO disclosed
US-20220119404-A1 METHOD FOR PRODUCING CYCLIC ENOL ETHER COMPOUND KAO CORPORATION (JP) 2022-04-21 US disclosed
CN-112771051-B Method for producing cyclic enol ether compound 花王株式会社 2022-04-05 CN disclosed
EP-3862356-A1 METHOD FOR PRODUCING CYCLIC ENOL ETHER COMPOUND Kao Corporation (JP) 2021-08-11 EP disclosed
EP-3303278-A1 PROCESS FOR PREPARING 3-METHYLCYCLOPENTADECANE-1,5-DIONE BASF SE (DE) 2018-04-11 EP disclosed
WO-2016193330-A1 PROCESS FOR PREPARING 3-METHYLCYCLOPENTADECANE-1,5-DIONE BASF SE (DE) 2016-12-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250214920-A1 METHOD FOR PRODUCING CYCLIC DIKETONE COMPOUND CYP4F2, DUOX1, BCKDK KDM1A 2384/4885
US-20220119404-A1 METHOD FOR PRODUCING CYCLIC ENOL ETHER COMPOUND ERG28, ADH1A, SQLE KDM1A 1886/4885
US-20250214921-A1 METHOD FOR PRODUCING CYCLIC DIKETONE COMPOUND HSD17B7, HSD17B12, BCKDK KDM1A 3537/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.